UA111434C2 - Фармацевтична композиція, що містить фімасартан і гідрохлортіазид - Google Patents

Фармацевтична композиція, що містить фімасартан і гідрохлортіазид

Info

Publication number
UA111434C2
UA111434C2 UAA201500674A UAA201500674A UA111434C2 UA 111434 C2 UA111434 C2 UA 111434C2 UA A201500674 A UAA201500674 A UA A201500674A UA A201500674 A UAA201500674 A UA A201500674A UA 111434 C2 UA111434 C2 UA 111434C2
Authority
UA
Ukraine
Prior art keywords
hydrochlorothiazide
pharmaceutical composition
composition containing
containing fimasartan
fimasartan
Prior art date
Application number
UAA201500674A
Other languages
English (en)
Inventor
Че Хак Кхім
Кхюн Ван Нам
Со Хун Парк
Чу Вон Кхім
Сан Йоп Кхім
Original Assignee
Борюн Фармасьютікал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49783403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA111434(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Борюн Фармасьютікал Ко., Лтд. filed Critical Борюн Фармасьютікал Ко., Лтд.
Publication of UA111434C2 publication Critical patent/UA111434C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується фармацевтичної композиції, що містить фімасартан, його фармацевтично прийнятну сіль, його гідрат або його сольват, гідрохлортіазид, його фармацевтично прийнятну сіль, його гідрат або його сольват, зв'язуючу речовину, що характеризується в'язкістю від 20 мПа⋅с до 1000 мПа⋅с при
UAA201500674A 2012-06-28 2013-04-30 Фармацевтична композиція, що містить фімасартан і гідрохлортіазид UA111434C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120070359A KR101414873B1 (ko) 2012-06-28 2012-06-28 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
PCT/KR2013/003734 WO2014003305A1 (ko) 2012-06-28 2013-04-30 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물

Publications (1)

Publication Number Publication Date
UA111434C2 true UA111434C2 (uk) 2016-04-25

Family

ID=49783403

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201500674A UA111434C2 (uk) 2012-06-28 2013-04-30 Фармацевтична композиція, що містить фімасартан і гідрохлортіазид

Country Status (21)

Country Link
US (1) US9457094B2 (uk)
EP (1) EP2868316B1 (uk)
JP (1) JP6145506B2 (uk)
KR (1) KR101414873B1 (uk)
CN (2) CN104602676A (uk)
AU (1) AU2013281582B2 (uk)
BR (1) BR112014032764B1 (uk)
CA (1) CA2877444C (uk)
CL (1) CL2014003525A1 (uk)
CO (1) CO7240413A2 (uk)
ES (1) ES2654207T3 (uk)
IN (1) IN2015DN00645A (uk)
MX (1) MX351521B (uk)
MY (1) MY165075A (uk)
PE (1) PE20150607A1 (uk)
PH (1) PH12014502876A1 (uk)
RU (1) RU2613900C2 (uk)
SG (1) SG11201408666SA (uk)
UA (1) UA111434C2 (uk)
WO (1) WO2014003305A1 (uk)
ZA (1) ZA201409508B (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105395552A (zh) * 2014-09-05 2016-03-16 南京华威医药科技开发有限公司 一种含非马沙坦及其盐的固体制剂
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염
MX387327B (es) * 2016-01-27 2025-03-18 Boryung Pharm Composición farmacéutica para prevenir o tratar nefropatía diabética
KR102233673B1 (ko) * 2016-01-27 2021-03-30 보령제약 주식회사 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR102201396B1 (ko) * 2017-11-30 2021-01-11 보령제약 주식회사 피마살탄을 포함하는 약학적 조성물
KR20220162456A (ko) * 2021-06-01 2022-12-08 주식회사 보령 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
CN120037195B (zh) * 2023-09-28 2025-11-28 浙江百代医药科技有限公司 一种硫辛酸药物组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
HRP20040649B1 (en) * 2002-01-16 2012-12-31 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
ES2523729T3 (es) 2006-06-16 2014-12-01 Lek Pharmaceuticals D.D. Composición farmacéutica que comprende hidroclorotiazida y telmisartán
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
CN102397278A (zh) * 2010-09-19 2012-04-04 鲁南制药集团股份有限公司 一种抗高血压药物组合物
CN102485228B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102485227B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102058602B (zh) * 2010-12-21 2013-04-10 中国药科大学 一种稳定的含氯沙坦钾和氢氯噻嗪的口服固体制剂

Also Published As

Publication number Publication date
BR112014032764B1 (pt) 2021-12-07
US9457094B2 (en) 2016-10-04
US20150147394A1 (en) 2015-05-28
RU2613900C2 (ru) 2017-03-21
IN2015DN00645A (uk) 2015-06-26
MX2014015841A (es) 2015-07-17
CN110496122A (zh) 2019-11-26
JP2015525745A (ja) 2015-09-07
KR101414873B1 (ko) 2014-07-03
CA2877444A1 (en) 2014-01-03
CA2877444C (en) 2017-08-01
KR20140006233A (ko) 2014-01-16
PH12014502876B1 (en) 2015-02-23
ES2654207T3 (es) 2018-02-12
MY165075A (en) 2018-02-28
EP2868316A4 (en) 2016-02-17
SG11201408666SA (en) 2015-03-30
PE20150607A1 (es) 2015-05-16
PH12014502876A1 (en) 2015-02-23
JP6145506B2 (ja) 2017-06-14
BR112014032764A2 (pt) 2017-06-27
CN104602676A (zh) 2015-05-06
RU2015102553A (ru) 2016-08-20
CO7240413A2 (es) 2015-04-17
MX351521B (es) 2017-10-18
CL2014003525A1 (es) 2015-04-10
EP2868316B1 (en) 2017-12-06
WO2014003305A1 (ko) 2014-01-03
ZA201409508B (en) 2016-08-31
AU2013281582A1 (en) 2015-02-05
AU2013281582B2 (en) 2016-06-09
EP2868316A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
IN2014DN10670A (uk)
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
ZA201509016B (en) Compositions, methods & systems for respiratory delivery of three or more active agents
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
EP3450449A3 (en) Peptide compositions
IN2015DN03998A (uk)
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
PH12018500377A1 (en) Novel annelated benzamides
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
IN2014DN10449A (uk)
PH12018501709A1 (en) Naphthridinedione derivatives
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
PH12015502632A1 (en) Cxcr7 receptor modulators
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
PH12016500461A1 (en) Polyethylene glycol-containing composition
EA201400444A1 (ru) Производные 2-оксопиперидинила
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
UA114396C2 (uk) Фармацевтична композиція з антиішемічною та антигіпертензивною дією
IN2013DE00880A (uk)
UA112586C2 (uk) Похідні бензімідазолпроліну
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
IN2013MU03801A (uk)